Septerna Stock
Septerna Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jeffrey T. Finer
- Employees
- 123
- Market cap
- $1.7 B
- IPO
- 25/10/2024
- Web
- septerna.com
Septerna Inc is a healthcare company in the biotechnology industry based in the United States. Founded in 2019 and headquartered in South San Francisco, the company is led by CEO Jeffrey T. Finer. As a clinical-stage biotechnology company, Septerna Inc focuses on the discovery and development of G protein-coupled…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Septerna stock: price history
1D
-2.9%
1W
-5.3%
1M
-5.4%
6M
+39.1%
YTD
+30.4%
1Y
+61.1%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~32% stronger price swings than usual
Ask the agents about Septerna
Analyst assessment of Septerna
PRICE TARGET LOW
US$43.00
CONSENSUS
US$50.40
MEDIAN
US$49.00
PRICE TARGET HIGH
US$60.00
1
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 19/08/2026
Septerna stock metrics
P/E
-67.31
P/B
4.23
EV/EBITDA
-41.57
RETURN ON EQUITY
-3.4%
NET MARGIN
-48.7%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
41.9%
FLOAT SHARES
19,545,970
AVG. DAILY VOLUME (30D)
387,837
Insider transactions (SEC)
Long Daniel D.
Long Daniel D.
Third Rock Ventures V, L.P.
Third Rock Ventures V, L.P.
RA CAPITAL MANAGEMENT, L.P.
Institutional holders
Comparable stocks
Frequently asked questions about Septerna stock
What does Septerna do?
Septerna Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jeffrey T. Finer, the company employs around 123 people.
The IPO was on 25/10/2024; the stock trades on NASDAQ under the ticker SEPN.
What do analysts say about Septerna stock?
9 analysts rate the stock, the consensus is Buy (as of 19/08/2026).
The average price target is US$50.40, ranging from US$43.00 to US$60.00, with a median of US$49.00.
This is an external assessment, not a statement by Market Jury.
When does Septerna report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 32% stronger than usual.
Does Septerna pay a dividend?
No, Septerna currently does not pay a dividend.
Which stocks are comparable to Septerna?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Septerna stock analyzed?
Clicking "Analyze stock" lets five strategies assess Septerna against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.